Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,597.60
(
-0.52%
)
Dow Jones
46,021.43
(
0.00%
)
Brent Oil
104.37
(
-0.06%
)
Bitcoin
70,507.12
(
0.87%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: laker9029 post# 103576

Tuesday, 09/07/2010 8:14:36 AM

Tuesday, September 07, 2010 8:14:36 AM

Post# of 257262

It appears that this was a high-risk action that could have been avoided. What was the reasoning for doing this particular trial (2 unapproved drugs) at this point in time?

All-oral regimens are the future of HCV therapy. The drug-drug-interaction study of IDX184+IDX320 in healthy volunteers was a prerequisite for running a combination trial in HCV patients.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now